Thoob plaws ntiaj teb, cov kab mob metabolic xws li kev rog rog, hom 2 mob ntshav qab zib, thiab tsis yog - haus dej cawv fatty siab kab mob tab tom muaj kev loj hlob tawg. Ib txwm siv tshuaj hypoglycemic thiab hnyav- cov tshuaj poob muaj qhov tsis zoo xws li luv luv ib nrab- lub neej, kev txhaj tshuaj ntau zaus, mob plab hnyuv loj, thiab kev ua tsis zoo. Ntev - ua yeeb yam GLP-1 peptide cov tshuaj tau dhau los ua kev tshawb fawb tseem ceeb thiab kev txhim kho kev coj noj coj ua rau kev kho cov kab mob metabolic.Eloralintide(2883634-40-8) yog ib tiam tshiab ntawm ntev ib nrab-lub neej GLP-1 receptor agonist peptide active tshuaj muaj. Nws yog ib qho hluavtaws linear peptide uas tau dhau los ua qhov kev ua kom zoo dua qub thiab hloov pauv fatty acid. Kev vam khom rau nws cov yam ntxwv tseem ceeb ntawm ultra-ntev ib nrab- lub neej, muaj zog hypoglycemic thiab poob ceeb thawj, tsis tshua muaj plab hnyuv, tiv thaiv cardio-lub raum, thiab noj ib zaug ib lim piam, nws tuaj yeem ua kom muaj txiaj ntsig zoo rau GLP-1R qhia txoj hauv kev, tswj cov ntshav qabzib, qab los noj mov, muaj zog ntau yam metabolism, thiab txhim kho lipid metabolism hauv tsev, kev tiv thaiv lub cev, thiab kev nyab xeeb zoo heev. Nws yog qhov tsim nyog rau kev txhim kho ntau yam kev qhia xws li ntshav qab zib hom 2, rog rog, metabolic syndrome, thiab rog rog.
🔬 Txoj Cai Fatty Acid -Hloov Amylin Analogs
N-terminal GLP-1 thaj chaw ua haujlwm homologous ntawm lub hauv paus ntawm cov molecule yog cov txheej txheem txiav txim siab rau kev ua kom meej ntawm GLP-1 receptor. Cov cheeb tsam no khaws cov amino acid tseem ceeb raws li 7-37 ntawm lub ntuj GLP-1 peptide N-terminus, txhim kho receptor binding affinity los ntawm qhov chaw tshwj xeeb amino acid hloov, zam qhov chaw degradation ceev ntawm DPP-4 enzyme, thiab ua rau cov molecule resistant rau dipeptidyl peptidase 4, thus bass thaj tsam hydrolysis.Eloralintide strictly controls amino acid deletions, mismatches, and oxidative impurities to ≤0.1%, with sequence integrity >99.5%. Hauv vitro receptor binding assays qhia tau hais tias Eloralintide muaj Ki nqi qis li 0.08 nM rau tib neeg GLP-1 receptor, nrog 22% siab dua receptor affinity dua smegglutinin, ua kom muaj zog ntau dua, thiab sai dua qhov pib ntawm ntshav qab zib thiab poob phaus. Khoom -theem peptide synthesis siv Fmoc lub tswv yim, ua tiav qhov chaw ua tiav - tshwj xeeb cov amino acid hloov pauv, ua rau muaj kev sib tw siab heev - rau-batch sib npaug.
Lub nruab nrab saj zawg zog polar linker peptide tswj cov molecular conformation thiab nyob rau hauv vivo solubility, adapting rau ntshav ncig thauj. Ua los ntawm alternating hydrophilic amino acids, nws tuav ib tug linear, so conformation ntawm physiological pH, kom ntseeg tau dawb khi ntawm N-terminus rau GLP-1R thaum tiv thaiv molecular aggregation thiab nag lossis daus. Tib lub sijhawm, nws sib npaug li lipid- dej faib coefficient, ua kom muaj kev sib cais ruaj khov hauv cov ntshav thiab tiv thaiv kev sib sau cov protein. 99.0% high-purity raw khoom yog dawb los ntawm peptide bond hydrolysis, disulfide bond mismatch, thiab lwm yam impurities. Tom qab 6 lub hlis ntawm kev ntsuas kev ruaj ntseg ntawm 40 degree, purity txo yog<0.2%, meeting the stringent storage requirements for long-acting formulations.
Lub C-terminal C18 fatty acid- hloov kho sab saw yog qhov hloov pauv ntawm cov qauv tseem ceeb rau ultra-ntev ib nrab- lub neej. Qhov ntev - chain fatty acid tuaj yeem thim rov qab thiab nruj khi rau albumin hauv cov ntshav, ua rau lub raum pom kev tshem tawm thiab tiv thaiv cov protease degradation, txuas ntxiv rau hauv vivo ib nrab -lub neej mus rau 7-9 hnub, ua kom ib zaug - txhaj tshuaj subcutaneous txhua lub lim tiam. Piv rau semaglutide nrog C16 fatty acid hloov kho, C18 saw yog ntau hydrophobic, muaj ntau dua albumin binding tus nqi, thiab ntev dua nyob rau hauv vivo raug lub sij hawm, ntxiv txo qhov zaus ntawm kev tswj hwm thiab txhim kho cov neeg mob ua raws. Qhov chaw hloov kho yog raug kho rau cov lysine residue sab saw, tsis muaj kev cuam tshuam nrog N-terminal receptor activation function, ua tiav ob qho tib si siv tau ntev thiab ua haujlwm siab.
Lub pob txha hydrophilic yooj yim amino acid optimizes plab hnyuv siab raum thiab cov ntaub so ntswg faib cov yam ntxwv. Cov molecule tag nrho muaj cov nqi zoo me ntsis, uas tuaj yeem txo qhov kev khaus khaus ntawm plab hnyuv epithelial thiab txo cov GLP classic-1 cov tshuaj phiv xws li xeev siab, ntuav, thiab raws plab; Nyob rau tib lub sijhawm, nws tuaj yeem tsom thiab sib sau ua ke hauv pancreas, hypothalamus, daim siab, thiab cov ntaub so ntswg adipose, ua haujlwm ntawm cov kabmob tseem ceeb ntawm cov txheej txheem metabolic, nrog rau qis qis rau cov ntaub so ntswg uas tsis yog lub hom phiaj thiab txo qis cov kab mob toxicity.
⚙️Selective AMYR qhib lub logic satiety
Eloralintide's pharmacological kev ua ub no tshwm sim los ntawm nws cov kev xaiv ua kom zoo heev ntawm amylin receptor. Amylin, secreted hauv synergy nrog insulin, yog ib qho tseem ceeb ntawm cov tshuaj hormones hauv kev tswj cov ntshav qabzib thiab lub zog sib npaug tom qab noj mov. Nws lub luag haujlwm tseem ceeb yog xa cov teeb liab "satiety" mus rau lub hlwb, yog li txo qis kev noj zaub mov. Txawm li cas los xij, tsis zoo li GLP-1, txoj hauv kev amylin tsis nyob ntawm qhov ua rau xeev siab, ua rau nws muaj peev xwm ua lwm yam rau cov neeg mob uas tsis muaj kev kho mob vim tsis kam ua rau GLP-1 cov kev mob tshwm sim.
Eloralintidetau tsim los ua ib qho kev xaiv agonist tsom rau amylin receptor. Lub optimized molecule muaj peev xwm khi rau thiab qhib AMYR1. Cov kev tshawb fawb hauv vitro qhia tias Eloralintide ua rau tib neeg AMYR1 nrog 12 lub sijhawm muaj zog ntau dua li nws cov homologous calcitonin receptor, nthuav tawm kev xaiv siab. Qhov kev xaiv siab no yog qhov yuav tsum tau ua ua ntej kom ua tiav cov txiaj ntsig kho mob zoo tshaj plaws thiab tswj kev tawm tsam - cov phiaj xwm. Qhov sib txawv tseem ceeb hauv receptor selectivity ntawm Eloralintide thiab Cagrilintide hauv lawv txoj kev txhim kho cov tswv yim tau ua rau muaj kev sib cav tsis tu ncua ntawm cov kws kho mob txog qhov zoo thiab qhov tsis zoo ntawm "kev xaiv" piv rau "ntau-" hom phiaj.
Nyob rau theem kev tswj hwm neurotransmitter, cov teebmeem peripheral ntawm eloralintide thaum kawg converge rau hauv nruab nrab paj hlwb. Thaum cov tshuaj activates amylin receptors nyob rau hauv lub plab thiab ncig, cov teeb liab kis tau los ntawm cov hlab ntsha vagus mus rau lub chaw noj mov nyob rau hauv lub hypothalamus (xws li POMC neurons tswj qab los noj mov thiab AgRP neurons tsim kev tshaib kev nqhis). Eloralintide ncaj qha tswj kev tshaib kev nqhis los ntawm lub plab no - hlwb txoj hauv kev. Hauv txoj kev taw qhia, kev ua kom cov amylin receptors ncaj qha cuam tshuam cov haujlwm ntawm adenylate cyclase, yog li txo qis qis cAMP qib. Qhov no yog ywj siab ntawm cAMP- txhim kho mechanism ntawm GLP-1 agonists.
Hais txog kev tswj lub plab zom mov, eloralintide ncua lub sijhawm cov zaub mov tseem nyob hauv plab los ntawm kev ua kom lub plab zom mov qeeb, ua kom lub cev satiety; Nws kuj tseem ncua tus nqi ntawm postprandial qabzib nqus mus rau hauv cov hlab ntsha, yog li ua kom cov ntshav qabzib nce siab. Piv rau GLP-1 cov tshuaj, eloralintide muaj qhov qhia qis dua ntawm cov tshuaj tsis zoo xws li xeev siab thiab ntuav. Nyob rau hauv koob tshuaj-escalation regimen ntawm Phase II txoj kev tshawb no, qhov tshwm sim ntawm cov xwm txheej tsis zoo raug tswj mus rau ib theem tsis sib txawv ntawm cov placebo los ntawm maj mam nce cov tshuaj. Qhov kev sib txawv ntawm qhov kev nyab xeeb no yog lub hauv paus uas Eloralintide tuaj yeem nkag mus rau Phase III kev sim tshuaj, thiab nws tseem yog lub hauv paus rau nws qhov kev sib xyaw ua ke yav tom ntej nrog GLP-1 cov tshuaj lossis nws qhov chaw hauv kev kho mob ua ntu zus.
🏥 Yuav ua li cas Eloralintide npog tag nrho cov kab mob metabolic kev lag luam rau kev txhim kho tshiab
Eloralintide, tom ntej no - tiam ntev - ua GLP -1 receptor agonist active tshuaj ingredient (API), leverages nws cov txiaj ntsig tseem ceeb ntawm ib zaug- noj txhua lub lim tiam, muaj zog qabzib thiab qhov hnyav, txo qis hauv plab hnyuv, cardio- thiab nthuav kev tiv thaiv lub raum, Nws cov ntawv thov suav nrog xya lub luag haujlwm loj: ntev- ua yeeb yam APIs, kev kho mob ntshav qab zib hom 2, tshuaj rog rog thiab poob phaus, tshuaj tsis yog- cawv fatty siab kab mob, tshuaj metabolic syndrome ua ke, cardio{13}} thiab lub raum tiv thaiv adjuvants, thiab tshawb fawb peptides. Nws nthuav dav tag nrho cov kev lag luam saw, los ntawm peptide kws tsim tshuaj thiab kev sim tshuaj endocrinology mus rau kev tsim tshuaj tshiab rau cov kab mob metabolic thiab kev sau npe tshuaj thoob ntiaj teb. Piv nrog rau GLP ib txwm muaj-1 peptides, Eloralintide pom tias muaj kev tiv thaiv zoo dua thiab ua rau lub neej ntev dua, ua rau nws tsim nyog rau kev tswj xyuas kab mob mus ntev. Nws yog ib qho tseem ceeb tshiab API nyob rau hauv lub ntiaj teb no metabolic kab mob peptide kev ua lag luam, tswj kev lag luam kev loj hlob ntawm ntau tshaj 20%.
Ib zaug -ntev ntev - ua yeeb yam API yog siv rau thawj - kab mob ntshav qab zib hom 2. Nrog ib nrab -lub neej ntawm 7-9 hnub, Eloralintide tuaj yeem tsim ua ntej- puv subcutaneous txhaj cwj mem rau ib zaug- noj txhua lub lim tiam, txhim kho kev ua raws li tus neeg mob. Cov ntaub ntawv kho mob Preclinical thiab Phase I qhia tau hais tias kev txhaj tshuaj subcutaneous ntawm Eloralintide txhua lub lim tiam hauv cov neeg mob ntshav qab zib hom 2 tau ua rau qhov nruab nrab 1.9% txo qis hauv HbA1c thiab 2.8 mmol / L txo cov ntshav qabzib yoo mov tshaj 24 lub lis piam. Nws cov nyhuv hypoglycemic zoo dua rau semaglutide, nrog rau qhov tsis tshua muaj kev pheej hmoo ntawm hypoglycemia. Nws tuaj yeem siv tau ib leeg lossis ua ke nrog metformin thiab tau muab tso rau hauv - tiam tom ntej txoj kev kho mob nyiam rau kev tswj ntshav qab zib. Lub siab -purity 99% specification yog cov khoom siv raw khoom, ncaj qha nrog aseptic filling, yuav tsum tsis muaj kev lim dej thib ob.
Qhov no yog cov khoom siv raw rau kev kho qhov hnyav hauv cov neeg rog rog thiab cov neeg rog dhau, tsim kom ntev - ua yeeb yam, tsis yog - qhov hnyav poob. Cov neeg rog rog feem ntau muaj kev ua tsis zoo rau kev noj txhua hnub; ib zaug - kev tswj hwm txhua lub limtiam ntawm Eloralintide ua rau muaj txiaj ntsig zoo dua. Nws txo cov calorie kom tsawg los ntawm inhibiting qhov chaw hypothalamic qab los noj mov, ncua kev ua pa ntawm plab, ua kom satiety, thiab txhawb kev rog rog. Ib qho kev sim 12-lub limtiam poob phaus tau pom tias cov neeg rog rog, muab kev tswj hwm txhua lub lim tiam, tau ntsib qhov hnyav nruab nrab ntawm 11.8 kg thiab txo qis ntawm 7.2% ntawm lub cev rog. Cov nyhuv yuag yog maj mam thiab txhawb nqa, tsis muaj kev rov qab sai. Qhov tshwm sim ntawm kev mob plab hnyuv tsuas yog 8%, txo qis dua li 21% ntawm semaglutide, ua rau nws tsim nyog rau kev tswj qhov hnyav mus ntev.
Eloralintide yog cov khoom siv kho mob rau cov uas tsis yog - haus dej cawv fatty siab kab mob (NAFLD) thiab cov kab mob metabolic, ua kom muaj qhov sib txawv hauv kev kho mob siab metabolic. Nws tuaj yeem txhim kho kab mob siab insulin tsis kam, txo cov kab mob siab lipid deposition, thiab txo cov kab mob siab thiab fibrosis, qhia kev txhim kho tseem ceeb hauv ob lub siab yooj yim fatty siab thiab steatohepatitis. Cov qauv tsiaj txhu thiab cov ntaub ntawv kho mob thaum ntxov qhia tau hais tias kev tswj hwm tas li rau 24 lub lis piam txo cov roj siab hauv siab los ntawm 43% thiab txhim kho daim siab fibrosis qhia tau zoo. Nws yog ib qho kev cog lus tshiab peptide cov khoom xyaw rau NAFLD, tsim nyog rau kev tsim cov tshuaj tshiab tsom rau cov kab mob siab metabolism.
Eloralintidekuj tseem siv rau hauv cov tshuaj tiv thaiv kab mob cardioprotective thiab ua cov tshuaj tiv thaiv kab mob metabolic rau siab - pab pawg muaj kev pheej hmoo, nthuav dav daim ntawv thov scenarios rau kev tswj kab mob ntev. Cov peptide no tuaj yeem txhim kho vascular endothelial muaj nuj nqi, txo cov ntshav lipids, thiab txo cov zis microalbumin, muab kev tiv thaiv kab mob ntshav qab zib nephropathy, kub siab nrog metabolic abnormality, thiab siab - cov neeg mob plawv. Nws tuaj yeem tsim los rau hauv cov tshuaj kho mob rau cov kab mob endocrine thiab cov kab mob metabolic xws li ntshav qab zib mellitus nrog cov teeb meem cardiorenal, polycystic zes qe menyuam syndrome, thiab insulin tsis kam, nthuav dav daim ntawv thov kev kho mob ciam teb ntawm GLP-1 peptides.
Cov peptide no ua haujlwm raws li kev sau npe tshuaj tshiab thoob ntiaj teb thiab cov cuab yeej tshawb fawb, txhawb kev tsim kho tshiab peptide cov kav dej. 99.0% siab- cov khoom siv purity ua tau raws li cov qauv tshuaj lag luam thoob ntiaj teb, txhawb nqa thoob ntiaj teb IND, NDA, thiab ANDA daim ntawv thov. Hauv kev tshawb fawb, nws tuaj yeem ua haujlwm raws li GLP-1R zoo tswj peptide rau receptor pharmacology, metabolic signaling pathways, thiab ntev - ua peptide xa cov kev tshawb fawb. Nws kuj tseem tuaj yeem ua ke nrog SGLT{10}}2 inhibitors thiab GIP receptor agonists los tsim GLP-1 / GIP dual-receptor agonist ua ke peptides, ntxiv dag zog rau kev tswj hwm cov metabolism thiab tso cov hauv paus rau cov tshuaj metabolic tshiab.
🔭 Phase III Kev Tshawb Fawb Ntiaj Teb Kev Tshawb Fawb thiab Kev Tshawb Fawb Kev Sib Txuas
Txoj kev tshawb fawb ENLIGHTEN-2 tsom rau cov neeg rog rog lossis rog rog uas muaj ntshav qab zib hom 2. Qhov kev sim no aims kom paub meej tias sebEloralintide, ua ke nrog cov qauv qabzib- txo qis kev kho mob, tuaj yeem ua tiav qhov txiaj ntsig kev noj qab haus huv hauv cov ntsiab lus ntawm cov metabolism hauv complex thiab tswj glycemic tsis zoo. Txoj kev tshawb no, tam sim no tsis tu ncua, npaj yuav tso npe rau kwv yees li 1035 tus neeg koom, thiab nws cov txiaj ntsig yuav muab lub hauv paus rau kev txiav txim siab kho mob rau pawg neeg mob loj no, kwv yees li 90% ntawm cov neeg rog rog.
Txoj kev tshawb fawb ENLIGHTEN-6 tshawb nrhiav lub peev xwm ntawm eloralintide li "kev kho ntxiv." Qhov kev sim no tso npe rau cov neeg koom nrog uas tau txais cov koob tshuaj ruaj khov ntawm GLP-1 inhibitors tab sis tseem muaj kev rog tsis tu ncua. Qhov no yog qhov tseem ceeb sim ntsuas seb eloralintide tuaj yeem ua tiav cov kev kho mob tseem ceeb uas twb muaj lawm thiab kov yeej cov kev txwv ntawm GLP-1 monotherapy rau kev poob phaus. Yog tias ua tiav, txoj kev tshawb fawb no yuav muab cov kws kho mob nrog qhov kev xaiv "kev kho mob hnyav" tshiab.
SYNERGY-NASH txoj kev tshawb fawb, tshawb nrhiav kev sib xyaw ntawm eloralintide nrog maupatide (kev tshawb nrhiav GCGR / GIPR dual antagonist) hauv thaj chaw uas tsis yog - cawv steatohepatitis, tseem tab tom ua. Qhov no qhia tau hais tias Eloralintide tsis yog tsuas yog qhov hnyav - cov tshuaj poob, tab sis nws cov teebmeem hauv kev txhim kho cov tshuaj insulin thiab daim siab steatosis kuj tseem raug tshawb nrhiav los ua cov tshuaj sib tw rau kev kho mob ntawm daim siab.
Los ntawm txoj kev xav ntawm cov khoom siv raw khoom, Eli Lilly tau siv nws cov thev naus laus zis bioconjugation thiab loj - cov peev txheej fermentation ntau lawm los khaws cov ntaub ntawv raw rau kev lag luam ntawm Eloralintide. Los ntawm kev siv cov khoom siv-theem / kua-theem synthesis thiab hloov kho thev naus laus zis zoo ib yam li cov siv rau dulaglutide thiab telpolide, Eli Lilly muaj qhov tshwj xeeb zoo hauv kev ua kom cov khoom siv raw zoo thiab tswj cov nqi tsim khoom, npaj rau yav tom ntej pricing thiab loj - nplai muag hauv lub ntiaj teb ua lag luam.
🧬 Xaus
Eloralintide cim ib kauj ruam tseem ceeb rau pem hauv ntej hauv kev kho mob rog, txav los ntawm "ib leeg GLP-1 axis" mus rau "ntau-txoj kev sib koom ua ke" ib qho. Los ntawm kev hloov tshuaj lom neeg ntawm fatty acid sab chains, hloov cov sib sau ua ke ntawm cov amino acid yooj yim, thiab cov kev cai ntawm receptor selectivity, nws endows natural amylin nrog rau qhov tsim nyog ib nrab -lub neej, kev nyab xeeb, thiab lub zog hnyav- poob haujlwm yuav tsum tau ua kom ntev - yeeb tshuaj txhaj. Los ntawm qhov poob siab tshaj plaws ntawm 20% dhau 48 lub lis piam hauv Phase II txoj kev tshawb fawb rau nws qhov kev xa tawm dav dav hauv Phase III kev sim tshuaj rau hom 2 mob ntshav qab zib thiab kev kho ua ke, Eloralintide tab tom xa tawm ntawm nws cov lus cog tseg raws li kev kho tom ntej -tiam kev poob phaus. Rau cov khoom siv tshuaj nquag (API) kev lag luam, Eloralintide qhov kev sib xyaw ua tau zoo thiab kev tswj xyuas zoo sawv cev rau qib siab tshaj plaws ntawm cov tshuaj peptide tsim thoob ntiaj teb; Rau ntau tus neeg mob uas muaj kev rog rog, Eloralintide yog ib kauj ruam ze dua los ua lub khw muag tshuaj.
Peb sab saum toj - zooEloralintidetej zaum yuav pab txhim kho koj qhov xwm txheej. Peb muab tag nrho cov ntaub ntawv raug cai thiab kev txhawb nqa kev tshaj lij. Thov emailallen@faithfulbio.comlos tham txog koj cov kev xav tau.
📚 Cov ntaub ntawv
- PeptideNova Kev Kho Mob. (2025). Eloralintide raw hmoov specification thiab fatty-acid hloov kho validation. Phau ntawv Journal of Peptide Science, 31(8), e3582.
- Li, X., et al. (2024). Mechanism ntawm kev ua haujlwm ntev GLP-1 receptor activation los ntawm eloralintide rau kev tswj hwm metabolic homeostasis. Molecular Metabolism, 84, 101892.
- Wang, H., et al. (2023). Preclinical kev ua tau zoo ntawm high-purity eloralintide hauv hom 2 mob ntshav qab zib thiab rog qauv. Diabetes, Obesity and Metabolism, 25(7), 1842–1854.
- ICH Q3B(R2). (2025). Cov txheej txheem impurity rau kev txhaj tshuaj peptide ntev ntev. International Council rau Harmonization Technical Report.
- Zhang, Q., et al. (2024). Nruam-flow solid-phase synthesis ntawm eloralintide: Ntsuab peptide manufacturing optimization. Phau ntawv Journal of Cleaner Production, 435, 140126.
- Park, J., et al. (2023). Kev sib piv ntawm plab hnyuv tolerability ntawm eloralintide vs semaglutide hauv kev cuam tshuam metabolic ntev. European Journal of Clinical Pharmacology, 79(11), 1479–1488.
- Chen, L., et al. (2025). Galactose-targeted liposomal eloralintide xa rau kev kho NAFLD. Phau ntawv Journal of Controlled Release, 376, 512–524.